Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy

Intervirology

Volumn 48, Issue 4, 2005, Pages 230-238

  Tae, Hun Kim ^a   Kyung, A Kim ^a   Young, Seok Lim ^a   Gwak, Geum Youn ^a   Yoon, Jung Hwan ^a   Gyeong, Hoon Kang ^b   Lee, Hyo Suk ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Early viral dynamics; High dose induction interferon; Response prediction

Indexed keywords

INTERFERON; LG INTERMAX ALPHA; LG RIBAVIRIN; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MYALGIA; NAUSEA; PREDICTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TITRATION;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 20444440291     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084600     Document Type: Article

References (32)

1. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
2. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26(suppl 1):2S-10S.
3. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, Almasio P: Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-828.
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
5. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campanone A, Filice G, Piccinino F: Premature discontinuation of interferon plus ribavirin for adverse effects: A multicenter survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1633-1639.
6. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103-107.
7. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Munda-Steindl P, Hegenbarth K, Gangl A, Vogel W: Australian Hepatitis Study Group. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34:1006-1011.
8. De Ledinghen V, Trimoulet P, Winnock M, Foucher J, Bourliere M, Desmorat H, Canva V, Capron D, Levy S, Mion F, Mannant PR, Chene G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group: Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol 2002;36:672-680.
9. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T: Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997;92:61-65.
10. Yamaji K, Hayashi J, Kawakami Y, Furusyo N, Sawayama Y, Kishihara Y, Etoh Y, Kashiwagi S: Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J Clin Gastroenterol 1998;26:193-199.
11. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990; 86:1764-1767.
12. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.
13. Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, et al: Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993;8:150-156.
14. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Doskeland B, Maeland A, Lund-Tonnesen S, Myrvang B: Effect of combined interferon-α induction therapy and ribavirin on chronic hepatitis C virus infection: A randomized multicenter study. Scand J Gastroenterol 2002;37:226-232.
15. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
16. Bekkering FC, Brouwer JT, Schalm SW, Elewaut A: Hepatitis C: Viral kinetics. Hepatology 1997;26:1691-1693.
17. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
18. Iino S, Hino K, Yasuda K: Current state of interferon therapy for chronic hepatitis C. Intervirology 1994;37:87-100.
19. Hu KQ, Vierling JM, Redeker AG: Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.
20. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
22. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30: 787-793.
23. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000;119:1317-1323.
24. Han CJ, Lee HS, Kim HS, Choe JH, Kim CY: Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases. Korean J Intern Med 1997;12:21-27.
25. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:1426-1432.
26. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Auperin A, Degott C, Benhamou JP, Erlinger S, Marcellin P: Predictors of sustained response to interferon-α therapy in chronic hepatitis C. J Hepatol 1998;29:214-223.
27. Lee SS: Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003;17:611-621.
28. European Association for the Study of the Liver: Consensus Statement. EASL International Consensus Conference on Hepatitis C, Paris, Feb 26-28, 1999. J Hepatol 1999;30:956-961.
29. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, Albrecht JK, Dienstag JL: Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001;8:414-420.
30. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J: Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-218.
31. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334: 77-81.
32. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.